Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

744
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
744
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

621
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
621

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardiomyopathy genetic testing: insights into demographics, counseling, and cascade screening.

Future cardiology·2025
Same author

Outcomes of a multidisciplinary approach to management of mavacamten in obstructive hypertrophic cardiomyopathy.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2024
Same author

Transitioning disopyramide to mavacamten in obstructive hypertrophic cardiomyopathy: A case series and clinical guide.

Pharmacotherapy·2023
Same author

Heart-liver-kidney transplantation for AL amyloidosis using normothermic recovery and storage from a donor following circulatory death: Short-term outcome in a first-in-world experience.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2023
Same author

Thin filament cardiomyopathies: A review of genetics, disease mechanisms, and emerging therapeutics.

Frontiers in cardiovascular medicine·2022
Same author

The Impact of Health Care Disparities on Patients With Heart Failure.

Journal of cardiac failure·2022

Related Experiment Video

Updated: Mar 27, 2026

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

10.1K

Mechanical Circulatory Support: Current Status and Future Directions.

Jorge Silva Enciso1

  • 1Cardiology Division, Department of Medicine, University of California San Diego.

Progress in Cardiovascular Diseases
|January 19, 2016
PubMed
Summary
This summary is machine-generated.

Left ventricular assist device (LVAD) therapy offers improved survival for advanced heart failure (AHF) patients but faces challenges. Future innovations aim to reduce complications and expand LVAD accessibility.

Keywords:
Heart failureHeart transplantationLeft ventricular assist deviceMechanical circulatory support

More Related Videos

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.8K
The Intra-Aortic Balloon Pump
06:13

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

25.8K

Related Experiment Videos

Last Updated: Mar 27, 2026

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

10.1K
Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.8K
The Intra-Aortic Balloon Pump
06:13

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

25.8K

Area of Science:

  • Cardiology
  • Medical Devices
  • Heart Failure Management

Background:

  • Advanced heart failure (AHF) presents a significant and growing public health challenge.
  • Left ventricular assist devices (LVADs) have emerged as a crucial therapeutic option for AHF, enhancing survival and quality of life.
  • Despite benefits, LVAD therapy is associated with complications, limiting its widespread application.

Purpose of the Study:

  • To review the historical development of LVADs.
  • To analyze the clinical outcomes and current challenges associated with LVAD therapy.
  • To discuss future directions and potential advancements in LVAD technology and adjunct therapies for AHF.

Main Methods:

  • Literature review of historical data.
  • Analysis of clinical outcomes from existing studies.
  • Discussion of current challenges and future research directions in LVAD therapy.

Main Results:

  • LVADs have demonstrated efficacy in improving survival and quality of life for patients with advanced heart failure.
  • Complications remain a significant hurdle, impacting broader patient eligibility and therapeutic success.
  • Emerging adjunct therapies and technological advancements hold promise for mitigating adverse events.

Conclusions:

  • LVAD therapy is a vital treatment for advanced heart failure, offering substantial patient benefits.
  • Addressing current complications and embracing technological innovation are critical for expanding the role of LVADs.
  • Future research should focus on refining device technology and integrating supportive therapies to optimize LVAD treatment outcomes.